Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment - Khatri, Amit; Dutta, Sandeep; Marbury, Thomas C.; Preston, Richard A.; Rodrigues, Lino; Wang, Haoyu; Awni, Walid M.; Menon, Rajeev M. (Clinical pharmacokinetics, 2017)
Keywords: Aged; Anilides - administration & dosage; Anilides - adverse effects; Anilides - pharmacokinetics; Antiretroviral drugs; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - pharmacokinetics; Antiviral drugs; Carbamates - administration & dosage; Carbamates - adverse effects; Carbamates - pharmacokinetics; Comorbidity; Drug dosages; Drug Therapy, Combination; Family medical history; Female; Hepacivirus - drug effects; Hepacivirus - metabolism; Hepatitis; Hepatitis C; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - epidemiology; Humans; Infections; Interferon; Internal Medicine; Kidney diseases; Kidney Diseases - blood; Kidney Diseases - drug therapy; Kidney Diseases - epidemiology; Liver; Macrocyclic Compounds - administration & dosage; Macrocyclic Compounds - adverse effects; Macrocyclic Compounds - pharmacokinetics; Male; Medicine; Medicine & Public Health; Middle Aged; Original Research Article; Pharmaceuticals; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Proteins; Ritonavir - administration & dosage; Ritonavir - adverse effects; Ritonavir - pharmacokinetics; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Survival analysis; Treatment Outcome; Uracil - administration & dosage; Uracil - adverse effects; Uracil - analogs & derivatives; Uracil - pharmacokinetics; Normal Renal Function; Severe Renal Impairment; Renal Impairment; Telaprevir; Ritonavir